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2Abstract
Over half of all cardiovascular (CV) events could be prevented by improved diet. This 
is reflected in government targets for fruit/vegetable intake, yet these are variable 
across the world (UK: 5-a-day; USA: 9-a-day), do not identify specific 
fruits/vegetables, and prove hard to achieve. Mounting evidence from prospective 
studies, supported by recent randomised controlled trials suggest that the benefits of 
fruits/vegetables may be due to bioactive substances called flavonoids. Specifically 
one sub-class of flavonoids, the anthocyanins, responsible for the red/blue hue, are 
receiving growing attention. Although promising data is emerging from cohort 
studies, and cell/animal studies, proof of efficacy from longer-term randomised 
controlled trials, and an understanding of the importance of differential metabolism in 
relation to clinical efficacy are distinctly lacking. Diet related ill-health are among the 
leading priorities of our time and simple dietary change, including incorporating a few 
portions of anthocyanin-rich fruit into our diet could have a significant impact at a 
public health level.
Background 
In an era where preventive medicine is becoming increasingly important, due to an 
expanding ageing population and increasing prevalence of obesity, an optimised diet 
is central for improving CV health. A sub-optimal diet is currently the leading risk 
factor for both disability and death worldwide (Lim et al. 2012) . Worldwide, chronic 
diseases have been projected to costs $17 trillion of cumulative economic loss from 
2011-2030 including healthcare costs and reduced productivity (Bloom et al. 2011). 
In the UK, the largest economic burden to the National Health Service (NHS) relates 
to a poor diet, with food-related ill-health costing the NHS £5.8 million per year 
(Scarborough et al. 2011). Although improved treatments have resulted in significant 
declines in incidence and mortality rates, cardiovascular disease (CVD) remains a 
considerable burden, in terms of ill-health, mortality and associated costs. In 2012-13 
alone the NHS in England spent £6.8 billion on CVD, predominantly in secondary 
care and costs are set to rise further (Bhatnagar et al. 2015). Unless there are 
continued improvements in prevention past gains will not be sustained. Although 
>50% of contemporary public health problems could be prevented through dietary 
change (Ezzati and Riboli 2013) it is still unclear what constitutes a healthy diet for 
different individuals: what are the key constituents in fruits/vegetables for optimal 
health, what are their physiological and molecular mechanisms of action, what is 
their metabolic fate, how extensive is inter-individual variability in metabolism and 
does this variability impact on CV health?
Fruit and CV health
Data suggest that diets rich in fruits are the third most important modifiable factor for 
reducing global rates of non-communicable diseases (Ezzati and Riboli 2013). In a 
recent prospective study of over half a million Chinese adults, daily fruit intake was 
associated with 4 mmHg lower systolic blood pressure (BP), 0.5 mmol/L lower blood 
glucose levels and a 34% and 40% lower risk of incident major coronary events and 
CV mortality respectively (Du et al. 2016). If we assume that there is a causal 
3association, the authors calculate that 16% of deaths from CV could be attributed to 
low fruit intake and >560,000 deaths from CV each year (including 200,000 before 
age 70), could be prevented if fruit was consumed daily (Du et al. 2016). There was 
evidence of a dose-response relationship (Du et al. 2016) and the inverse 
associations could be causal given that fruit is a rich source of a number of bioactive 
constituents including flavonoids (Hartley et al. 2013; Hooper et al. 2008; Liu 2003). 
Growing evidence highlights the beneficial effect of flavonoids such as anthocyanins 
as likely key constituents in lowering CVD risk and the focus of this review relates 
only to the anthocyanin sub-class. 
Dietary flavonoids and the anthocyanin sub-class
Dietary flavonoids represent a diverse range of polyphenolic compounds that occur 
naturally in plant foods. Their structural complexity has led to their sub-classification 
as flavonols, flavones, flavanones, flavan-3-ols (and their oligomers, 
proanthocyanidins), isoflavones, and anthocyanins (Hooper et al. 2008). They are 
present in significant amounts in many commonly consumed fruits, vegetables, and 
beverages. 
         Anthocyanins are water-soluble plant pigments that are responsible for the 
red/blue colouration in plants, flowers, seeds and fruits (Smeriglio et al. 2016) and 
are predominantly found in the skin of fruit, except for berries where they are present 
in both the skin and flesh (Manach et al. 2004). They are present in a number of 
foods commonly consumed in the habitual diet with red, blue or purple fruits and 
vegetables containing concentrations ranging from 0.1% to up to 1.0% of dry weight 
(Pojer et al. 2013). Fruits such as berries, blackcurrants, red grapes, plums and 
cherries are rich dietary sources, as are fruit-derived products like red wine and 
juices; they are also present to a more limited extent in some vegetables such as 
radishes (Table 1, USDA 2014, (Perez-Jimenez et al. 2010). Although there is wide 
variability in levels depending on growing and storage conditions, two servings of 
fresh blueberries contain, on average, 240mg, and two glasses of red wine 56 mg 
(Table 1). 
        Anthocyanins are glycosides of anthocyanidins and it is currently thought that 
only the following six are of relevance to the human diet (cyanidin, delphinidin, 
malvidin, pelargonidin, peonidin, petunidin). In plants they play a key role in 
pollination and by absorbing light, protect plants from ultra-violet (UV)-induced 
damage(Castañeda-Ovando et al. 2009). Habitual dietary intake of anthocyanins is 
variable and in the US estimated daily intake was on average 12.5 mg/day  (Wu et 
al. 2006), while in Europe mean intakes for men ranged from 19.8 (the Netherlands) 
to 64.9 mg/ day (Italy), and for women, from 18.4 (Spain) to 44.1 mg/day (Italy) 
(Zamora-Ros et al. 2011). Fruits are the most common dietary source, and in the EU 
were responsible for up 61% of habitual intake, predominantly from apples, pears, 
berries, stone fruit and grapes. Wine contributed 14.4-24.5% of intake across Europe 
(contributing 24.5% in both Southern and Northern regions) (Zamora-Ros et al. 
2011). In the US the main dietary sources are strawberries and blueberries (Cassidy 
et al. 2011). Although intakes are variable, given their presence in commonly 
consumed fruits the potential to increase intake is readily achievable. Just 
consuming 1-2 portions of either strawberries, raspberries or blueberries would 
significantly increase intakes of anthocyanins to levels that have been reported to be 
associated with a reduction in risk of CVD (Bhagwat et al. 2013; Cassidy et al. 2013; 
Cassidy et al. 2011; Jennings et al. 2012; McCullough et al. 2012). 
4Population-based studies
A number of prospective cohort studies and cross-sectional studies have examined 
the associations between habitual anthocyanin intakes and cardiovascular disease 
(CVD) outcomes or biomarkers of CVD risk, predominantly based in US populations 
(Tables 2).  Coronary heart disease (CHD) and non-fatal myocardial infarction (MI) 
were examined in five studies, with evidence in four to suggest that increased 
habitual anthocyanin intake is significantly associated with a reduction in risk of CHD 
by 12-32% in multivariate analyses (Cassidy et al. 2016; Cassidy et al. 2013; 
McCullough et al. 2012; Mink et al. 2007) (Table 2). The magnitude of the protective 
effect of increased anthocyanin intake was smaller in the older women and men (12-
21%) compared to a study which focused on younger and middle-aged women 
where a 32% reduction in risk was observed comparing extremes of anthocyanin 
intake. Median intakes were 12 mg per day in these women, and when extreme 
deciles of intake were compared those in the top decile had a 47% reduction in risk 
of MI, suggesting a continual dose-response at higher levels of intake (Cassidy et al. 
2013); for every 15 mg increase in anthocyanin intake, the relative risk of MI 
decreased by 17% in the multivariate model (Cassidy et al. 2013). The relationship 
between anthocyanin intake and CVD mortality was also examined in several 
studies, with one study showing no association (Mursu et al. 2008), while two others 
observed 9-14% reductions in risk comparing higher with lower intake (McCullough 
et al. 2012; Mink et al. 2007).The impact of increased anthocyanin intake on stroke 
has to date been  examined in five studies, and although there was long-term follow-
up, there is currently no evidence for a protective effect (Cassidy et al. 2016; Cassidy 
et al. 2012; McCullough et al. 2012; Mink et al. 2007; Mursu et al. 2008) (Table 2).  
In relation to CV risk biomarkers, prospective studies and cross-sectional  data 
provide mechanistic support for the observed decrease in CHD risk with increased 
anthocyanin intakes, with evidence that higher intakes improve arterial stiffness ( 
assessed by pulse wave velocity) and blood pressure (Cassidy et al. 2011; Jennings 
et al. 2012).The magnitude of the associations observed for systolic blood pressure 
(-4 mmHg decrease with higher intake) were similar to those previously reported for 
stopping smoking and 2 fold higher than that observed following a small (1.4 portion) 
increase in fruit/vegetable intake (Jennings et al. 2012). The available data on the 
effects on inflammatory biomarkers are equivocal (Table 2, (Chun et al. 2008; 
Jennings et al. 2014; Landberg et al. 2011) although more recent work, using a 
combined inflammatory score suggests that reduced inflammation may be a key 
pathway (Cassidy et al. 2015); recent prospective data also support the importance 
of weight maintenance (Bertoia et al. 2016). Interestingly the greatest reduction in 
hypertension was observed in the younger/ middle-aged women, supportive 
evidence for the observed reduction in risk of MI in this age group (Cassidy et al. 
2013; Cassidy et al. 2011). Higher habitual anthocyanin intakes (35mg, half a portion 
of berries), resulted in a 0.7 mIU/L reduction in insulin levels (Jennings et al. 2014) 
similar to the effects of a low-fat diet (Shikany et al. 2011) or 1hr/day walking (Fung 
et al. 2000). The magnitude of associations are clinically relevant and of significant 
public health importance. However, future research should focus on identifying and 
validating panels of anthocyanin metabolites that reflect intake and subsequent 
metabolism so that associations of bioavailable anthocyanins (and inter-individual 
variability) can be assessed in future prospective cohort studies.
5Randomised controlled trials (RCTs)
     To date, very few RCTs have examined the impact of anthocyanins on 
cardiovascular health relative to other sub-classes such as the flavan-3-ols present 
in tea and cocoa (Hooper et al. 2012) .  In several short term interventions (< 2mth 
duration), anthocyanin rich food intake (predominantly blueberries) resulted in a 5-
6% decrease in both systolic and diastolic BP (Basu et al. 2010; Erlund et al. 2008; 
Johnson et al. 2015) and favourable changes in arterial stiffness (Dohadwala et al. 
2011; Johnson et al. 2015). A recent 3-month dose-response study (strawberries, 78 
and 155 mg/d anthocyanins)  demonstrated beneficial effects on total and LDL-
cholesterol levels following high intake (Basu et al. 2010), and the effect was 
mediated by improvements in cholesterol efflux capacity (Zhu et al. 2014). In a 6-
month study, inflammatory biomarkers were reduced following anthocyanins (320 
mg/d) in hypercholesterolemia patients (Zhu et al. 2013), while acute intake of 
strawberries (39mg anthocyanins) attenuated the 6hr postprandial inflammatory 
response (Edirisinghe et al. 2011). These preliminary RCT findings are supported by 
animal and in vitro data. Anthocyanins inhibit atherosclerosis development, alter cell 
signalling pathways involved in vascular inflammation, and reduce infarct size 
following coronary occlusion and perfusion (Lamy et al. 2008; Toufektsian et al. 
2008).  Mechanistic studies also suggest an impact on whole body insulin action 
(DeFuria et al. 2009; Inaguma, Han, and Isoda 2011; Stull et al. 2010).  However, to 
date, very few carefully controlled human trials have examined the effects of 
anthocyanins on insulin resistance (IR) (Stull et al. 2010). Therefore, although 
promising data is emerging from cohort studies, and cell/animal studies, proof of 
efficacy from longer-term RCTs and an understanding of the importance of 
metabolism in relation to clinical efficacy are distinctly lacking. 
Bioavailability, metabolism and potential importance of the microbiome
Following ingestion, anthocyanins undergo extensive metabolism; microbiota likely 
play a key metabolic role, catabolising unabsorbed flavonoids into smaller molecules 
such as phenolic and aromatic acids, which are also absorbed (Manach et al. 2005; 
Williamson and Clifford 2010). For anthocyanins consumed in the diet, the parent 
compounds may not be responsible for bioactivity; instead this may be mediated by 
metabolites present in the systemic circulation (Czank et al. 2013; Williamson and 
Clifford 2010). Data from the limited available trials show that following ingestion 
there is extensive variability in metabolite levels.
This wide inter-individual variability in metabolism (15-99% of the ingested intake 
recovered as a wide range of urinary metabolites (Czank et al. 2013; Manach et al. 
2005; Cassidy and Minihane 2017) suggest that metabolism may be critical in 
explaining the differential responses in CV risk biomarkers observed in clinical trials 
(responders v non-responders). This heterogeneity in responsiveness to anthocyanin 
intake may relate to a number of factors, including post-absorptive variability in 
Phase I and II metabolism (including reduction, hydrolysis, glucuronidation, 
sulphation), but the microbiome is likely to be critical as it plays a key role in 
anthocyanin metabolism (Cassidy and Minihane 2017; Czank et al. 2013; Williamson 
and Clifford 2010). Furthermore, it is likely that intake alters the composition and 
function of the gut microbiome (Anhe et al. 2015; Roopchand et al. 2015) and 
conversely, that the microbiota enhance the metabolism of anthocyanins, but this 
bidirectional relationship has not yet been addressed. To understand the importance 
of metabolism, particularly microbiome-mediated biotransformation, in explaining the 
6CV health effects of flavonoids a combination of epidemiological studies and dietary 
intervention trials (acute and chronic) are needed. 
  
Is metabolism key to clinical efficacy of anthocyanins and do the microbiota 
play a role?
Our recent human bioavailability trials highlighted extensive inter-individual variability 
in anthocyanin absorption and metabolism, identified a range of novel downstream 
metabolites and provided substantial evidence to suggest that the major circulating 
metabolites are phenolic breakdown products derived from microbial metabolism 
(Czank et al. 2013; de Ferrars et al. 2014). Microbial metabolites are more bioactive 
than the parent compounds in in vitro models exerting greater vascular and anti-
inflammatory activity than the metabolites formed and absorbed in the small intestine 
(Amin et al. 2015; de Ferrars et al. 2014; di Gesso et al. 2015; Krga et al. 2016).  
Together, these data provide further evidence that the bioactivity of anthocyanins is 
highly likely attributed to their microbially-derived metabolites, which are present in 
the circulation significantly longer and at much higher levels than the parent 
anthocyanins (Czank et al. 2013; de Ferrars et al. 2014). Colonic metabolism has 
long been speculated to be a major contributor to overall metabolism (Williamson 
and Clifford 2010) and our stable isotope study provided the first evidence in humans 
of the extent of metabolism, suggesting it is key in the production of hippuric acid 
and a range of phenolic acids, including vanillic and ferulic acid with serum levels 
reaching >2M (magnitudes higher than the parent compounds) and remaining in 
the circulation >48 hrs following intake (Czank et al. 2013; de Ferrars et al. 2014).
Strong interplay: anthocyanins and the microbiome: The large heterogeneity in 
the bioactivity and bioavailability of anthocyanin metabolites formed following 
ingestion, including the extensive range of gut metabolites identified, supports 
strong-interplay. Whether anthocyanins alter the composition and function of the gut 
microbiome or the microbiota enhances the metabolism of anthocyanins is a key 
area for future research. In relation to nutrition research, in a cross-sectional study, 
(n=178 elderly subjects) habitual diet-driven microbiota alterations were associated 
with measures of frailty and inflammation (Claesson et al. 2012), and a small 2-
month intervention study (n=15 women), showed changes in 
Gammaproteobacteria and the Firmicute Erysipelotrichi microbial communities 
(Spencer et al. 2011). In a recent small RCT (n=9) high levels of bifidobacteria were 
associated with increased levels of flavonoid microbial metabolites following 
polyphenol-rich wine intake (Boto-Ordonez et al. 2014). In animals, anthocyanin 
intake resulted in significant effects on gut microbial community structure, including a 
reduction in the ratio of Firmicutes to Bacteroidetes and an increase in Akkermansia 
(mucin-degrading Verrucomicrobia) muciniphila; changes that provided protection 
against a high fat diet, resulting in an improvement in insulin sensitivity and the 
inflammatory response (Anhe et al. 2015; Roopchand et al. 2015). These data from 
mice provide the first evidence that either the gut microbiota play a substantial role in 
mediating the health effects of anthocyanins and/or that anthocyanin intake 
enhances the health effects of the microbiota. Clinical studies to determine if these 
effects are also observed in humans are urgently needed. Currently, the identity of 
the main microbiota phyla and species that modulate anthocyanin metabolism in 
7humans are unknown, and data from adequately powered acute and long-term RCTs 
investigating the potential of microbiota diversity to explain associations between 
anthocyanins and CVD risk are completely lacking.
Future research priorities
There is growing evidence from prospective studies, animal studies and short-term 
trials of the potential cardiovascular health benefits of anthocyanins. The 
heterogeneity in the observed effects on CV disease endpoints and biomarkers may 
obscure the potential health benefits, therefore future research should focus on 
understanding inter-individual variability in metabolism following intake and the 
importance of the microbiome. Understanding if a differential capacity to metabolise 
anthocyanins affects CV health will allow us to develop strategies to enhance and 
optimise the health benefits. Anthocyanin-rich foods, predominantly from fruit, are 
readily incorporated into the diet and simple dietary change could have a significant 
impact in reducing CVD risk. 
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Table 1
Common dietary Sources of Anthocyanins
mg/100g* serving size mg/serving
Blueberries 163.3 1/2 cup 120.8
Blackberries 100.6 1/2 cup 70.4
Plums 56.0 1 medium 37.0
Red grapes 48.0 1/2 cup 36.5
Raspberries 48.6 1/2 cup 30.2
Red wine 19.3 5 oz 28.3
Cherries 32.0 1/2 cup 22.4
Strawberries 27.0 1/2 cup 20.5
Radishes 63.1 2 medium 5.7
*mg/100g based on USDA Database for the Flavonoid Content of Selected Foods, Release 3.1 (2014)
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Table 2. Observational studies examining the associations between dietary anthocyanin intakes and cardiovascular disease risk 
Author Intake (mg/d) Outcome measure Country, Gender
Age range
Population Multivariate-adjusted RR (95% CI), p-trend 
Highest versus lowest category
PROSPECTIVE STUDIES
Mink et al 
20071
Median (range) 
0.2 (0-1040) 
CHD mortality USA, Postmenopausal 
women 
55-69 y
34,489
16 y follow-up 
Cases = 1329
0.88 (0.78-0.99), p=0.03
McCullough 
et al 2012
Median (range)
3.8 (0-5.5) Q1 to 22.2 
(≥16.7) Q5
CHD mortality USA, Men (Mean age = 
70 y), Postmenopausal 
women (Mean age = 69 
y)
98,469 (38,180 men; 60,289 
women) 
7 y follow-up
Cases = 1286 (803 men, 483 
women)
Men & women: 0.79 (0.67-0.94), p=0.06
Men only: 0.81 (0.65-1.00) p=0.2
Women only:0.81 (0.60-1.07) p=0.2
Jacques et al 
2015
Median and IQR
9.1 (3.4-17.3) 1991-
1995 and 17.8 (8.1-
29.2) 2005-2008
CHD (incident) USA, 2880 men and 
women, Mean age = 54 y
2880
14.9 y follow-up, 261 CHD events
0.96 (0.85-1.08) p=0.49
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Author Intake (mg/d) Outcome measure Country, Gender
Age range
Population Multivariate-adjusted RR (95% CI), p-trend 
Highest versus lowest category
Cassidy et al 
2013
Mean (IQR)
12.3 (1.9-35.0)
CHD (incident and 
fatal)
USA, Premenopausal 
women
25-42 y 
93,600
18 y follow-up
Cases =  405
0.68 (0.49-0.96), p=0.047
Cassidy et al 
2016
0-613 range, IQR (3.9-
15)
CHD (incident and 
fatal)
USA, men
39-77 y
43,880
24 y follow-up
Cases = 4046 MI (2222 non-fatal) 
Total MI 0.97 (0.85-1.07) p=0.44
Fatal MI 1.10 (0.94-1.28) p=0.56
Non-fatal MI 0.87 (0.75-1.00) p=0.098
Mink et al 
20071
Median (range) 
0.2 (0-1040) 
Stroke mortality USA, Postmenopausal 
women 
55-69 y
34,489
16 y follow-up 
Cases = 469
1.01 (0.83-1.24) p=0.90
McCullough 
et al 2012
Median (range)
4.3 (0-6.2) Q1 to 20.4 
(≥15.0)  Q4
Stroke mortality USA, Men  (Mean age = 
70 y), Postmenopausal 
women (Mean age = 69 
y)
98,469 (38,180 men, 60,289 
women) 
7 y follow-up
Cases = 573 (281 men, 292 
women)
Men & women: 0.95 (0.75-1.20) p=0.7
Men only: 0.84 (0.59-1.20) p=0.2
Women only:1.05 (0.76-1.46) p=0.6
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Author Intake (mg/d) Outcome measure Country, Gender
Age range
Population Multivariate-adjusted RR (95% CI), p-trend 
Highest versus lowest category
Mursu et al 
20081
Mean 
6.2
Ischemic stroke 
(incident)
Finland, Men
42-60 y
1950 
15 y follow-up
Cases =  102
0.88 (0.47-1.62) p=0.81
Cassidy et al 
2012
Median (range) 
8.9 (0-354.9)
Ischemic stroke 
(incident)
USA, Women  
30-55 y
69,622
14 y follow-up
Cases = 943
0.89 (0.72-1.11) p=0.59
Cassidy et al 
2016
0-613 range, IQR (3.9-
15)
Ischemic stroke 
(incident)
USA, men
39-77 y
43,880
24 y follow-up
Cases =  901 ischemic stroke
Ischemic stroke 0.93 (0.75-1.15) p=0.51
Mink et al 
20071
Median (range) 
0.2 (0-1040) 
CVD mortality USA, Postmenopausal 
women 
55-69 y
34,489
16 y follow-up 
Cases = 2316
0.91 (0.83-0.99) p=0.03
Mursu et al 
20081
Mean 
6.2
CVD mortality Men
42-60 y
1950
15 y follow-up
Cases = 153
0.99 (0.62-1.85) p=0.19
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Author Intake (mg/d) Outcome measure Country, Gender
Age range
Population Multivariate-adjusted RR (95% CI), p-trend 
Highest versus lowest category
McCullough  
et al 2012
Median (range)
3.8 (0-5.5) Q1 to 22.2 
(≥16.7)  Q5
CVD mortality Men (Mean age = 70 y), 
Postmenopausal women 
(Mean age = 69 y)
98,469
(38,180 men, 60,289 women) 
7 y follow-up
Cases = 2771 (1589 men)
Men & women: 0.86 (0.76-0.97) p=0.04
Men only: 0.91 (0.77-1.06) p=0.3
Women only:0.82 (0.69-0.99) p=0.06
Jacques et al 
2015
Median and IQR
9.1 (3.4-17.3) 1991-
1995 and 17.8 (8.1-
29.2) 2005-2008
CVD incidence USA, 2880 men and 
women mean age 54 y
2880
14.9 y follow-up, 518 CVD events
0.94 (0.86-1.02) p=0.14
Cassidy et al 
2011
Mean (IQR)
14.0 (5.4-17.8)
Incident 
hypertension
USA, Young/middle aged 
women
26-42 y
87,242
14 y follow-up 
Cases = 11,402
0.87 (0.81-0.92) p<0.0001
Cassidy et al 
2011
Mean (IQR)
12.5 (4.6-15.9)
Incident 
hypertension
USA, Older women
43-71 y
46,672
14 y follow-up 
Cases = 17,616
0.93 (0.88-0.98) p=0.02
Cassidy et al 
2011
Mean (IQR)
15.2 (5.8-19.3)
Incident 
hypertension
USA, Men
36-80 y
23,043
14 y follow-up 
Cases = 5,629
0.99 (0.90-1.09) p=0.82
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Author Intake (mg/d) Outcome measure Country, Gender
Age range
Population Multivariate-adjusted RR (95% CI), p-trend 
Highest versus lowest category
CROSS-SECTIONAL STUDIES
Cassidy et al 
2015
0-365 range Combined 
inflammation score
USA, middle-aged men 
and women
2375 Combined inflammation score
-0.71 (-1.17, -0.25)
Jennings et al 
2014
Mean ± SD (IQR)
17.8 ± 14.3 (8.4-23.8)
CRP UK, Women 
18-76 y
1997 -0.3 mg/L, p = 0.04  
Q5 vs. Q1
Landberg et al 
2011
Median 
10 
Inflammatory 
biomarkers
USA, Women 
43-70 y
1,087-1,598 No association for CRP, IL6 &  other 
inflammatory biomarkers;
higher intakes associated with lower IL-18 
levels (p = 0.014)
Jennings et al 
2012
Mean ± SD (IQR)
17.7 ± 14.9 (8.4-23.6)
Blood pressure
Augmentation 
index (AI)
UK, Women 
18-75 y
1,898 Peripheral systolic BP -4.0 mmHg (p=0.009) 
Central systolic BP -3.0±1.4 mmHg (p=0.017)
Central diastolic BP -1.9±1.0 mmHg (p=0.05)
MAP -2.3±1.2 mmHg (p=0.037)
Q5 vs. Q1 intake
PP and AI: no association
Jennings et al Mean ± SD (IQR) Pulse wave velocity UK, Women 728 PWV is 3.9% lower: -0.4 ± 0.22 m/s, p = 0.044  
19
Author Intake (mg/d) Outcome measure Country, Gender
Age range
Population Multivariate-adjusted RR (95% CI), p-trend 
Highest versus lowest category
2012 17.7 ± 14.9 (8.4-23.6) (PWV) 
Intima media 
thickness (IMT)
18-75 y Q5 vs. Q1
IMT: no significant association
Landberg et al 
2011
Median 
10 
Inflammatory 
biomarkers
USA, Women 
43-70 y
1,087-1,598 No association for CRP, IL6 &  other 
inflammatory biomarkers;
higher intakes associated with lower IL-18 
levels (p = 0.014)
Mursu et al 
20071
Mean 
7.5
Intima media 
thickness (IMT)
Finland, Men
42-60 y
1,380 No significant association (p=0.58)
Chun et al 
2008
Range (tertile 1 to 
tertile 3) 
0 - >22.6
CRP levels USA, Men and women 
19-70+ y
8,335
(4,225 men, 4,110 women)
-0.18 mg/L decrease 
tertile 1 vs. tertile 3 of intake (p < 0.05)
1Relies on data from earlier version of the USDA database on flavonoid contents in foods 2003 and additional analyses for anthocyanin contents of Finnish berries (Jacques 
et al. 2015; Mursu et al. 2007).
CHD, coronary heart disease, CVD, cardiovascular disease, MI, myocardial infarction, AI, augmentation index; BP, blood pressure; CRP, C-reactive protein; HDL, high-
density lipoprotein; IL, interleukin; IMT, intima media thickness MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; Q1 quintile 1, Q5 quintile 5
